SciSparc to Spin Off Clinical Pharma Portfolio
Ticker: SPRC · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: spin-off, pharmaceutical, clinical-stage
TL;DR
SciSparc spinning off clinical pharma assets to a new public company. Big move for pipeline focus.
AI Summary
On July 8, 2024, SciSparc Ltd. announced it has signed a non-binding letter of intent to spin off its advanced clinical-stage pharmaceutical portfolio into a publicly traded company. This strategic move aims to unlock the value of its pipeline assets and allow for focused development and potential future funding.
Why It Matters
This spin-off could allow SciSparc to focus on its core business while potentially creating a separate entity that attracts dedicated investment for its clinical-stage assets.
Risk Assessment
Risk Level: medium — The transaction is based on a non-binding letter of intent, meaning the final terms and completion are not guaranteed.
Key Players & Entities
- SciSparc Ltd. (company) — The company filing the report and announcing the spin-off.
- July 8, 2024 (date) — The date the press release regarding the spin-off was issued.
FAQ
What is the primary purpose of the spin-off announced by SciSparc Ltd.?
The primary purpose is to spin off SciSparc's advanced clinical-stage pharmaceutical portfolio into a publicly traded company.
What type of agreement has SciSparc Ltd. signed regarding the spin-off?
SciSparc Ltd. has signed a non-binding letter of intent for the spin-off.
When was the press release announcing this spin-off issued?
The press release was issued on July 8, 2024.
What is the SEC form number associated with this filing?
The SEC form number is 0001213900-24-059840.
What is SciSparc Ltd.'s principal executive office address?
SciSparc Ltd.'s principal executive office is located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Filing Stats: 330 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-07-08 16:35:02
Filing Documents
- ea0209069-6k_scisparc.htm (6-K) — 13KB
- ea020906902ex99-1_scisparc.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-059840.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: July 8, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3